cystic fibrosis

Discovering new compounds to treat cystic fibrosis is now more feasible as a result of work in the collaborative laboratory of Dr. Aleksander Edelman at INSERM in France. The research team identified new compounds using their novel functional assay that tests the function of the CFTR protein following the application…

A 39 year-old man with Cystic Fibrosis who was planning to scale Mount Everest in an effort to raise money and awareness for the disease is reportedly safe and making his way back from Everest’s base camp after a massive earthquake over the weekend ravaged the region leaving…

A new clinical study showed that AffloVest®, portable High Frequency Chest Wall Oscillation (HFCWO) vest, improved lung function scores in a cohort of adolescents with Cystic fibrosis. The study, entitled “An evidence-based study of adolescents with cystic fibrosis demonstrated that AffloVest® by International Biophysics contributed to improved…

An article published in the Journal of Clinical Microbiology provides important clues to understanding the cause of pulmonary exacerbations in patients with Cystic Fibrosis (CF).  The study, entitled, “Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over…

The Medicines Company recently announced in a news release that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for a new injectable formulation of the antibiotic MINOCIN® (minocycline). The news is significant for the cystic fibrosis community, as MINOCIN is…

A 39 year-old man with Cystic Fibrosis is attempting to become the first person with the disease to climb Mount Everest. Nick Talbot hopes that his perilous attempt to scale the highest and most famous mountain in the world will help to raise awareness and funds for CF while encouraging those…

The nonprofit affiliate of the Cystic Fibrosis Foundation (CFF), Cystic Fibrosis Foundation Therapeutics, Inc., will expand its research partnership with Genzyme in a collaboration that will be supported by $14 million in additional funding. The funding is expected to be invested in developing novel therapy options for patients…

DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. In Cystic Fibrosis, patients’ production of the CFTR protein and ENaC ion channel is abnormal, leading to a dysfunctional CFTR activity and over-activity of ENaC.

The FDA approval of the CFTR modulator, Kayldeco, in 2012 changed the paradigm of CF healthcare by providing a therapy to address the underlying cause of the disease. The previous paradigm in CF care was limited to only treat the symptoms of CF, such as inflammation, bacterial infection and…

The residential apartment brand MCLife, which belongs to MC Companies, is launching the #CFShoeSelfie campaign, with the main purpose of raising awareness about the chronic disease cystic fibrosis (CF). At a time when emails, social media, television, and advertisements bombard everyone with images that are easily forgotten, the company aims…